Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)'s price to sales ratio for trailing twelve month stands at 1.59, whereas its price to book ratio for most recent quarter sits at 1.00. The consensus recommendation by Thomson Reuters analysts is Outperform and their mean rating for the stock is 2.27 on scale of 1-5.
Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 33.94 on Tuesday. 6,110,029 shares of the company were exchanged.
Fourth quarter revenue was $6.5 billion, up 33% from the corresponding quarter of 2015, primarily due to the inclusion of Actavis generics business. Analysts expect the company to report profit per share of $4.83 on revenue of $23.69 billion. Bridge Creek Capital Management LLC now owns 20,604 shares of the company's stock valued at $1,035,000 after buying an additional 1,765 shares during the last quarter. Sales for the quarter mainly gained from solid performances at the company's worldwide wholesale and global company-owned retail businesses, offset by soft sales at the domestic wholesale segment.
Several sell side analysts reviewed their recommendations on Teva Pharmaceutical Industries Limited (NYSE:TEVA) where 6 analyst have rated the stock as Strong Buy, 8 analysts said it's a Buy, 13 rated the stock as Hold, 0 analysts reported Underperform and 0 analysts gave their recommendations as Sell. Cash flow from operations fell 12 percent to $1.4 billion.Teva reaffirmed its 2017 forecast of EPS between $4.90 and $5.30, on revenue of between $23.8 billion and $24.5 billion. The company's price sits -8.83% below from its 50-day moving average of $34.65 and -29.12% away from the stock's 200-day moving average which is $43.09. The company has a market cap of $34.45 billion, a PE ratio of 19.74 and a beta of 0.58.
Flynn Denied Discussing Sanctions With Russia. New Reports Say He Did
The New York Times' report on this added , "Federal officials who have read the transcript of the call were surprised by Mr. That would suggest that Flynn finally realized that tapes proving these discussions occurred might exist.
Price Target is basically a projection of future price of a company's stock by the expert analysis of investment analysts or investment firms. Jefferies Group LLC downgraded shares of Teva Pharmaceutical Industries Limited from a "buy" rating to a "hold" rating and decreased their price objective for the company from $69.00 to $40.00 in a research report on Sunday, December 4th. Citigroup Inc. reissued a buy rating and set a $47.00 price target on shares of Teva Pharmaceutical Industries Limited in a research report on Tuesday, February 7th. Morgan Stanley downgraded shares of Teva Pharmaceutical Industries Limited from an "overweight" rating to an "equal weight" rating and lowered their price objective for the company from $63.00 to $42.00 in a research report on Wednesday, November 16th.
The company also recently announced a quarterly dividend, which will be paid on Monday, March 20th. Shareholders of record on Thursday, March 2nd will be given a dividend of $0.34 per share. If you are viewing this article on another publication, it was stolen and republished in violation of USA and worldwide copyright & trademark legislation. This represents a $1.36 dividend on an annualized basis and a dividend yield of 4.00%. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2017/02/14/teva-pharmaceutical-industries-limited-teva-issues-fy17-earnings-guidance.html. Teva Pharmaceutical Industries Limited presently has a consensus rating of "Buy" and an average target price of $53.73. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines.
TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals.
Among analysts and investors, a widespread belief is that Teva could split in two-one side, the company's generics business, the other, its branded drug company.